Physician profile
Melissa Antonik
NPI 1316025372
$291.63
in general payments reported to CMS, 2019-2025
14 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.21 · 2023: $63.76 · 2024: $24.12 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $243.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $31.10 | 2025 | Tymlos |
| Amgen INC. | $29.70 | 2019-2025 | Evenity |
| Ascendis Pharma Endocrinology INC | $28.69 | 2025 | Yorvipath |
| Insulet Corporation | $24.45 | 2023 | Omnipod |
| Abbott Laboratories | $24.12 | 2024 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $22.63 | 2025 | Recorlev |
| Lilly USA, LLC | $21.62 | 2025 | Mounjaro, Zepbound |
| Beta Bionics, INC. | $20.80 | 2023 | Ilet Bionic Pancreas |
| Medtronic Minimed, INC. | $20.61 | 2019 | |
| Novo Nordisk INC | $19.26 | 2025 | Ozempic |
| Medtronic, INC. | $18.51 | 2023 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.17 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $14.97 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Antonik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.